DULOXETINE HYDROCHLORIDE (duloxetine) by Hetero is 12. Approved for the following conditions: major depressive disorder (mdd) in adults () generalized anxiety disorder (gad) in adults, older () diabetic peripheral neuropathic pain (dpnp) in adults () fibromyalgia (fm) in adults, older () chronic musculoskeletal pain in adults () duloxetine delayed-release capsules are indicated for the treatment of: major depressive disorder in adults generalized anxiety disorder in adults and 3 more indications. First approved in 2013.
Drug data last refreshed 1w ago
12.1 Mechanism of Action Although the exact mechanisms of the antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS. 12.2 Pharmacodynamics…
Worked on DULOXETINE HYDROCHLORIDE at Hetero? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
A Study Of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta Under Fed Conditions
A Study of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta
A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder